Releases - AstraZeneca

View:
 

Found press releases

 

Återköp av aktier i AstraZeneca PLC 17-21 maj 2012

5/22/2012 3:22 AM EST
REPURCHASE OF SHARES IN ASTRAZENECA PLC

AstraZeneca PLC announced that on 18 May 2012, it purchased for cancellation 600,000 ordinary shares of AstraZeneca PLC at a price of 2624 pence per share. Upon the cancellation of these shares, the number of shares in issue will be 1,265,183,783.

A C N Kemp

Company Secretary

21 May 2012

REPURCHASE OF SHARES IN ASTRAZENECA PLC

AstraZeneca PLC announced that on 17 May...

REPURCHASE OF SHARES IN ASTRAZENECA PLC

5/16/2012 10:21 AM EST
AstraZeneca PLC announced that on 15 May 2012, it purchased for cancellation 550,000 ordinary shares of AstraZeneca PLC at a price of 2654 pence per share. Upon the cancellation of these shares, the number of shares in issue will be 1,266,580,309. A C N Kemp Company Secretary 16 May 2012

REPURCHASE OF SHARES IN ASTRAZENECA PLC

5/15/2012 3:41 AM EST
AstraZeneca PLC announced that on 14 May 2012, it purchased for cancellation 525,500 ordinary shares of AstraZeneca PLC at a price of 2665 pence per share. Upon the cancellation of these shares, the number of shares in issue will be 1,267,111,010. A C N Kemp Company Secretary 15 May 2012

REPURCHASE OF SHARES IN ASTRAZENECA PLC

5/14/2012 3:27 AM EST
Further to the announcement of its irrevocable, non-discretionary share repurchase programme for the period 5 March 2012 to 11 May 2012, AstraZeneca PLC announced that under the terms of that programme it purchased for cancellation 315,751 ordinary shares of AstraZeneca PLC at a price of 2691 pence per share on 11 May 2012. Upon the cancellation of these shares, the number of shares in issue will be...

REPURCHASE OF SHARES IN ASTRAZENECA PLC

5/10/2012 5:01 AM EST
Further to the announcement of its irrevocable, non-discretionary share repurchase programme for the period 5 March 2012 to 11 May 2012, AstraZeneca PLC announced that under the terms of that programme it purchased for cancellation 316,391 ordinary shares of AstraZeneca PLC at a price of 2685 pence per share on 9 May 2012. Upon the cancellation of these shares, the number of shares in issue will be 1,268,256,452.

A...

REPURCHASE OF SHARES IN ASTRAZENECA PLC

5/9/2012 10:26 AM EST
Further to the announcement of its irrevocable, non-discretionary share repurchase programme for the period 5 March 2012 to 11 May 2012, AstraZeneca PLC announced that under the terms of that programme it purchased for cancellation 313,798 ordinary shares of AstraZeneca PLC at a price of 2709 pence per share on 8 May 2012. Upon the cancellation of these shares, the number of shares in issue will be 1,268,566,549.

A...

REPURCHASE OF SHARES IN ASTRAZENECA PLC

5/8/2012 2:50 AM EST
Further to the announcement of its irrevocable, non-discretionary share repurchase programme for the period 5 March 2012 to 11 May 2012, AstraZeneca PLC announced that under the terms of that programme it purchased for cancellation 311,479 ordinary shares of AstraZeneca PLC at a price of 2730 pence per share on 4 May 2012. Upon the cancellation of these shares, the number of shares in issue will be 1,269,166,468.

A...

REPURCHASE OF SHARES IN ASTRAZENECA PLC

5/4/2012 10:23 AM EST
Further to the announcement of its irrevocable, non-discretionary share repurchase programme for the period 5 March 2012 to 11 May 2012, AstraZeneca PLC announced that under the terms of that programme it purchased for cancellation 311,816 ordinary shares of AstraZeneca PLC at a price of 2727 pence per share on 3 May 2012. Upon the cancellation of these shares, the number of shares in issue will be 1,269,163,885.

A...

Återköp i AstraZeneca 25 april 2012 till 3 maj 2012

5/3/2012 9:03 AM EST
REPURCHASE OF SHARES IN ASTRAZENECA PLC

Further to the announcement of its irrevocable, non-discretionary share repurchase programme for the period 5 March 2012 to 11 May 2012, AstraZeneca PLC announced that under the terms of that programme it purchased for cancellation 313,590 ordinary shares of AstraZeneca PLC at a price of 2710 pence per share on 2 May 2012. Upon the cancellation of these shares, the number of...

FIRST QUARTER RESULTS 2012

4/26/2012 2:01 AM EST
London, 26 April 2012

First quarter results reflect challenging revenue picture. Pipeline strengthened by Amgen collaboration, the agreement to acquire Ardea Biosciences and positive CHMP opinion for FORXIGATM (dapagliflozin) in Europe.

Revenue for the first quarter was $7,349 million, down 11 percent at constant exchange rates (CER).

-Loss of exclusivity on several key brands accounted for 8 percentage points of...

AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, ...

View more


  CONTACT  
  • Anna Carbin-Åhlund - Press Contact
  • +468-553 269 39
  •